Optimi Labs Inc. is a wholly owned subsidiary of Optimi Health Corp.
Optimi Labs has developed an intellectual property (IP) strategy encompassing delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new formulations, testing and protocol regimens specific to mushroom-based products and synthetic psychedelic compounds.
To expedite innovation, Optimi Labs works with both academic and strategic development partnerships led by Chief Science Officer, Justin Kirkland.
Our 10,000 sq ft, EU-GMP analytical lab is designed both for research into the company’s proprietary formulations and extraction methods using:
Get updates directly to your inbox.
Optimi Health Corp.
21 Water St #600, Vancouver, BC V6B 1A1
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Products do not contain psilocybin